
|Articles|August 1, 2002
Long-term RCC survivors do not respond to cytokines
Orlando, FL-Most long-term survivors of metastatic renal cellcarcinoma do not achieve a response to cytokine treatment, according toresults of a pooled analysis by French researchers. Their findings suggesta lack of association between initial tumor regression on cytokine treatmentand long-term survival, except for the few patients who achieve completeregression.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
3
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
4
FDA approves first-line Zenflow system for the treatment of BPH
5















